New deputy in town
This article was originally published in The Rose Sheet
Executive Summary
Curtis Rosebraugh, MD, took over as CDER Division of OTC Drug Products deputy director effective Jan. 27. Rosebraugh previously worked as a medical officer in the Division of Pulmonary & Allergy Drug Products. Rosebraugh succeeds Linda Katz, MD, who left to head the Office of Cosmetics & Colors Sept. 3. Rosebraugh will report to Division of OTC Drug Products Director Charles Ganley, MD...
You may also be interested in...
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.